Absci Announces Interim Phase 1 Data From Its Trial Of ABS-201, An Investigational Anti-Prolactin Receptor Antibody; Study Medication Appears Well Tolerated, With Favorable Safety Data Across All Blinded Single Ascending Dose Cohorts

Absci Corporation

Absci Corporation

ABSI

0.00

Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period

First multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic alopecia (AGA) participants has been initiated

Interim proof-of-concept data anticipated in the second half of 2026, with full proof-of-concept data in early 2027

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.